4[3]Nierman DM, Schechter CB, Cannon LM, et al. Outcome prediction mcdel for very elderly critically ill patients. Crit Care Med, 2001,29:1853-1859.
5[7]Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med,2001,29 :S99-S106.
6[8]Murphy DB,Cregg N, Tremblay L, et al. Adverse ventila tory strategy causes pulmonary-to-systemic translocation of endotoxin. Am J Respir Crit Care Med,2000,162:27-33.
8BATES DW,MILLER EB ,CULLEN DJ,et al. Patient risk factors for adverse drug events in hospitalized patients [J]. Arch Intern Med,1999,159:2553-2560.
9WILHELM MP, ESTES L. Symposium on antimicrobial agentsPart Ⅻ. Vancomycin[ J]. Mayo Clin Proc, 1999,74(9) :928-935.
10ELTING LS, RUBENSTEIN EB, KURTIN D, et al. Mississippi mud in the 1990s. Risks and outcomes of vancomycin-associated toxicity in general oncology practice [J]. Cancer, 1998,83 (12): 2597-2607.
